ANALYTICAL QUANTIFICATION OF BOSUTINIB IN NANOCARRIER USING UV & HPLC: METHOD DEVELOPMENT & VALIDATION

Rishabh Agade; Ujban Hussain; Sagar Trivedi; Veena Belgamwar

doi:10.22159/ijap.2024v16i5.51394

Authors

Rishabh Agade Department of Pharmaceutical Sciences, RTM Nagpur University, Nagpur
Ujban Hussain
Sagar Trivedi Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj, Nagpur University, Nagpur, 440033 https://orcid.org/0000-0001-6764-0019
Veena Belgamwar Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj, Nagpur University, Nagpur, 440033

DOI:

https://doi.org/10.22159/ijap.2024v16i5.51394

Keywords:

Bosutinib, Lipidic nanocarriers, Cancer therapy, Drug delivery, Chromatographic analysis

Abstract

Introduction: Bosutinib (BST), a potent tyrosine kinase inhibitor, holds significant promise in cancer therapy, particularly in Breast Cancer treatment. This study focuses on the analytical quantification of BST in nanocarriers essential for quantification in term of targeted delivery and.

Methods: A comprehensive method development and validation process was undertaken utilizing UV-visible spectroscopy and High-performance liquid chromatography (HPLC). Preformulation studies confirmed the purity and physicochemical properties of BST. UV-visible spectroscopy established a calibration curve for BST and BST-loaded nanocarrier (BST-NCs), with precision, accuracy, limits of detection (LOD), and limits of quantification (LOQ) determined. HPLC analysis further validated BST quantification, ensuring the robustness and reliability of the analytical method.

Results: UV-visible spectroscopy revealed λmax for BST and BST-loaded nanocarrier, facilitating precise quantification. Method validation demonstrated excellent linearity, precision, and accuracy for both UV and HPLC methods. The LOD and LOQ values indicated the sensitivity of the developed methods, crucial for pharmaceutical analysis.

Conclusion: The developed UV and HPLC methods offer accurate and reliable quantification of BST in a nanocarrier, essential for optimizing drug delivery strategies and therapeutic outcomes in cancer treatment. This analytical approach contributes to advancing pharmaceutical research in precision medicine and targeted drug delivery systems.

Downloads

Download data is not yet available.

Author Biography

Ujban Hussain

Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj, Nagpur University, Nagpur, 440033

References

Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood [Internet]. 2012 Apr 12 [cited 2024 May 10];119(15):3403–12. Available from: https://pubmed.ncbi.nlm.nih.gov/22371878/

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leuk 2016 305 [Internet]. 2016 Feb 3 [cited 2024 May 10];30(5):1044–54. Available from: https://www.nature.com/articles/leu20165

Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol [Internet]. 2015 Sep 1 [cited 2024 May 10];90(9):755–68. Available from: https://pubmed.ncbi.nlm.nih.gov/26040495/

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol [Internet]. 2009 Jan 20 [cited 2024 May 10];27(3):469–71. Available from: https://www.researchgate.net/publication/23656152_Activity_of_Bosutinib_Dasatinib_and_Nilotinib_Against_18_Imatinib-Resistant_BCRABL_Mutants

Ahmed S, Mustaan N, Sheraz MA, Nabi SAA un, Ahmad I. Validation of a UV Spectrometric Method for the Assay of Tolfenamic Acid in Organic Solvents. J Pharm [Internet]. 2015 Dec 10 [cited 2024 May 10];2015:1–8. Available from: https://www.researchgate.net/publication/286542265_Validation_of_a_UV_Spectrometric_Method_for_the_Assay_of_Tolfenamic_Acid_in_Organic_Solvents

Trivedi S, Belgamwar V, Wadher K, Umekar M. Development and Validation of a UV Spectrophotometric Method for the Estimation of the Synthesized Lentinan–Congo Red Complex. J Appl Spectrosc [Internet]. 2022 May 1 [cited 2024 May 10];89(2):344–9. Available from: https://www.researchgate.net/publication/361117171_Development_and_Validation_of_a_UV_Spectrophotometric_Method_for_the_Estimation_of_the_Synthesized_Lentinan-Congo_Red_Complex

Chaursiya AC, L. Dumpala R. A Review on Revision of ICH Q2 (R1) and New ICH Q14 Guidance. Glob J Pharma Allied Sci. 2020 Nov 15;1(6):1–6.

Trivedi S, Belgamwar V, Wadher K. Development and Validation of Ultra Visible Spectrophotometric Method for the Estimation of Thymoquinone. Asian J Appl Chem Res. 2021;8(2):25–30.

Bhoyar V, Belgamwar VS, Trivedi S. Simultaneous Determination and Validation of Anti-Tubercular Drugs in Simulated Lungs Alveolar Macrophages Fluid by Ultraviolet-Visible Spectrophotometric Method. J Appl Spectrosc. 2022 Nov 1;89(5):892–7.

Wadher K, Trivedi S, Rarokar N, Umekar M. Development and assessment of rutin loaded transfersomes to improve ex vivo membrane permeability and in vitro efficacy. Hybrid Adv. 2024 Apr;5:100144.

Trivedi S, Belgamwar V, Wadher K. Analytical profiling of Lentinan in hybrid nanostructures for intranasal Delivery: Method development and Validation. Results Chem [Internet]. 2022 [cited 2024 May 10];4:100471. Available from: https://doi.org/10.1016/j.rechem.2022.100471

Aderibigbe BA. In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases. Pharmaceutics [Internet]. 2018 Jun 1 [cited 2024 May 10];10(2). Available from: /pmc/articles/PMC6027251/

Trivedi S, Deshpande A, Belgamwar V, Bhoyar V, Wadher K. Stability Indicating HPLC Method for Estimation of Thymoquinone in Nasal Simulated Fluid: Method Development and Validation . J Pharm Res Int [Internet]. 2021 [cited 2024 May 10];33(60A):233–40. Available from: https://www.sdiarticle5.com/review-history/79564

Trivedi S, Thool S, Wadher K, Bhalekar M, Bire P. Self-Assembling Dioscorea bulbifera loaded mixed micelles: Formulation optimization, in-vitro cytotoxicity and in-vivo pharmacokinetics. J Drug Deliv Sci Technol. 2021 Oct 1;65:102722.

Wadher K, Dabre S, Gaidhane A, Trivedi S, Umekar M. Evaluation of antipsoriatic activity of gel containing Pongamia pinnata extract on Imiquimod-induced psoriasis. Clin Phytoscience. 2021 Dec;7(1).

Trivedi S, Kause S, Belgamwar V. Intranasal delivery of poly (D-glucosamine) encrusted self-assembled lipidic nanovesicles to enhanced brain uptake of thymoquinone for management of Glioblastoma Multiforme. J Drug Deliv Sci Technol. 2023 Dec 1;90.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell [Internet]. 2005 [cited 2024 May 10];7(2):129–41. Available from: https://www.dora.lib4ri.ch/psi/islandora/object/psi%3A13267/

Trivedi S, Wadher K, Umekar M. Development of topical thymoquinone loaded polymer–lipid hybrid vesicular gel: in-vitro and ex-vivo evaluation. J Liposome Res. 2022;32(3):224–36.

Belgamwar VS, Bhoyar VT, Trivedi S, Pardeshi C V. Quantitative and qualitative analysis of direct nose-to-brain drug delivery. Direct Nose-to-Brain Drug Deliv Mech Technol Adv Appl Regul Updat. 2021 Jan 1;459–81.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol [Internet]. 2018 Jan 20 [cited 2024 May 10];36(3):231–7. Available from: https://pubmed.ncbi.nlm.nih.gov/29091516/